Logo image of CCXI

CHEMOCENTRYX INC (CCXI) Stock Fundamental Analysis

NASDAQ:CCXI - Nasdaq - US16383L1061 - Common Stock - Currency: USD

51.99  +0.03 (+0.06%)

After market: 51.99 0 (0%)

Fundamental Rating

3

CCXI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of CCXI have multiple concerns. CCXI is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CCXI has reported negative net income.
CCXI had a negative operating cash flow in the past year.
CCXI Yearly Net Income VS EBIT VS OCF VS FCFCCXI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -50M -100M

1.2 Ratios

Industry RankSector Rank
ROA -31.74%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CCXI Yearly ROA, ROE, ROICCCXI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -50 -100 -150 -200 -250

1.3 Margins

Industry RankSector Rank
OM -353.17%
PM (TTM) -357.01%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CCXI Yearly Profit, Operating, Gross MarginsCCXI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

CCXI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CCXI has been increased compared to 1 year ago.
The debt/assets ratio for CCXI is higher compared to a year ago.
CCXI Yearly Shares OutstandingCCXI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M
CCXI Yearly Total Debt VS Total AssetsCCXI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 9.70 indicates that CCXI is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.02 indicates that CCXI is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 9.7
ROIC/WACCN/A
WACC9.62%
CCXI Yearly LT Debt VS Equity VS FCFCCXI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 100M 200M 300M

2.3 Liquidity

CCXI has a Current Ratio of 4.54. This indicates that CCXI is financially healthy and has no problem in meeting its short term obligations.
CCXI has a Quick Ratio of 4.47. This indicates that CCXI is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 4.47
CCXI Yearly Current Assets VS Current LiabilitesCCXI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for CCXI have decreased by -6.78% in the last year.
The Revenue has grown by 72.49% in the past year. This is a very strong growth!
Measured over the past years, CCXI shows a very strong growth in Revenue. The Revenue has been growing by 21.96% on average per year.
EPS 1Y (TTM)-6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
Revenue 1Y (TTM)72.49%
Revenue growth 3Y-9.08%
Revenue growth 5Y21.96%
Sales Q2Q%548.81%

3.2 Future

CCXI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.34% yearly.
CCXI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 134.59% yearly.
EPS Next Y9.69%
EPS Next 2Y37.13%
EPS Next 3Y41.06%
EPS Next 5Y47.34%
Revenue Next Year117.77%
Revenue Next 2Y157.52%
Revenue Next 3Y130.02%
Revenue Next 5Y134.59%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CCXI Yearly Revenue VS EstimatesCCXI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B
CCXI Yearly EPS VS EstimatesCCXI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CCXI. In the last year negative earnings were reported.
Also next year CCXI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CCXI Price Earnings VS Forward Price EarningsCCXI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -26.68
CCXI Per share dataCCXI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as CCXI's earnings are expected to grow with 41.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.13%
EPS Next 3Y41.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CCXI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHEMOCENTRYX INC

NASDAQ:CCXI (10/19/2022, 8:04:24 PM)

After market: 51.99 0 (0%)

51.99

+0.03 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2022-08-08/amc
Earnings (Next)11-08 2022-11-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners0.37%
Ins Owner Change0%
Market Cap3.71B
Analysts52.31
Price Target53.04 (2.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.65%
Min EPS beat(2)-73.94%
Max EPS beat(2)12.63%
EPS beat(4)3
Avg EPS beat(4)-7.25%
Min EPS beat(4)-73.94%
Max EPS beat(4)29.7%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-41.92%
Min Revenue beat(2)-74.96%
Max Revenue beat(2)-8.87%
Revenue beat(4)1
Avg Revenue beat(4)-25.25%
Min Revenue beat(4)-74.96%
Max Revenue beat(4)29.07%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 99.51
P/FCF N/A
P/OCF N/A
P/B 15.68
P/tB 15.68
EV/EBITDA -26.68
EPS(TTM)-1.89
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.52
BVpS3.31
TBVpS3.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.74%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -353.17%
PM (TTM) -357.01%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.54
Quick Ratio 4.47
Altman-Z 9.7
F-Score3
WACC9.62%
ROIC/WACCN/A
Cap/Depr(3y)860.12%
Cap/Depr(5y)583.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
EPS Next Y9.69%
EPS Next 2Y37.13%
EPS Next 3Y41.06%
EPS Next 5Y47.34%
Revenue 1Y (TTM)72.49%
Revenue growth 3Y-9.08%
Revenue growth 5Y21.96%
Sales Q2Q%548.81%
Revenue Next Year117.77%
Revenue Next 2Y157.52%
Revenue Next 3Y130.02%
Revenue Next 5Y134.59%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.33%
OCF growth 3YN/A
OCF growth 5YN/A